CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤治疗的免疫治疗
英文原题：Immunotherapy for the treatment of multiple myeloma.
查看英文原题
Immunotherapy for the treatment of multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管多发性骨髓瘤治疗不断进步，多数患者最终仍会复发，并出现免疫逃逸和对标准治疗耐药。免疫治疗已成为强有力的肿瘤靶向细胞毒疗法，并具有诱导免疫记忆、降低复发风险的独特潜力。要开发能够产生持久应答的新疗法，必须了解晚期骨髓瘤中的免疫失调和功能障碍机制。过继细胞治疗，尤其CAR-T 细胞治疗，在难治性疾病中已显示出显著应答。进一步阐明免疫逃逸因素，以及治疗应答和耐药机制，对于开发下一代过继细胞疗法、指导新型联合治疗、并确定骨髓瘤治疗中引入免疫疗法的最佳时机至关重要。
展开英文摘要原文
Despite advances in treatment for multiple myeloma, the majority of patients ultimately develop relapsed disease marked by immune evasion and resistance to standard therapy. Immunotherapy has emerged as a powerful tool for tumor-directed cytotoxicity with the unique potential to induce immune memory to reduce the risk of relapse. Understanding the specific mechanisms of immune dysregulation and dysfunction in advanced myeloma is critical to the development of further therapies that produce a durable response.
Adoptive cellular therapy, most strikingly CAR T cell therapy, has demonstrated dramatic responses in the setting of refractory disease. Understanding the factors that contribute to immune evasion and the mechanisms of response and resistance to therapy will be critical to developing the next generation of adoptive cellular therapies, informing novel combination therapy, and determining the optimal time to incorporate immune therapy in the treatment of myeloma.
论文信息
- 作者
- Boussi LS、Avigan ZM、Rosenblatt J
- 第一作者单位
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States.Israel
- 通讯作者单位
- Division of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States.Israel
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36389674 · DOI 10.3389/fimmu.2022.1027385
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →